Shire’s Elaprase For Hunter Syndrome To Undergo Long-Term Outcomes Study
Executive Summary
Shire will do long-term follow up for its newly approved Hunter syndrome therapy Elaprase through a 15-year outcomes survey
You may also be interested in...
Shire Collaboration Brings Validation To ArmaGen’s Drug-Delivery Technology
While awaiting finalization of its merger with AbbVie, Shire signed a deal with privately held ArmaGen to license technology that could enable Elaprase to be delivered across the blood-brain barrier. That would enable the Hunter syndrome therapy to treat CNS manifestations of the disease as well as systemic symptoms.
Therapeutic Biologics Approvals Up In 2006, Overall BLA Approvals Steady
Overall 2006 biological license application approvals held steady from 2005 at 10 approvals, but the year saw a significant increase in approvals of therapeutic biologics
Therapeutic Biologics Approvals Up In 2006, Overall BLA Approvals Steady
Overall 2006 biological license application approvals held steady from 2005 at 10 approvals, but the year saw a significant increase in approvals of therapeutic biologics